Elsevier

Mayo Clinic Proceedings

Volume 95, Issue 8, August 2020, Pages 1701-1703
Mayo Clinic Proceedings

Brief report
Seasonality of Coronavirus 229E, HKU1, NL63, and OC43 From 2014 to 2020

https://doi.org/10.1016/j.mayocp.2020.05.032Get rights and content

Abstract

The possibility of seasonality of COVID-19 is being discussed; we show clinical microbiology laboratory data illustrating seasonality of coronaviruses 229E, HKU1, NL63, and OC43. The data shown are specific to the 4 studied coronaviruses and may or may not generalize to COVID-19.

Abbreviations and Acronyms

COVID-19
coronavirus disease of 2019
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2

Cited by (0)

Grant Support: Dr Patel reports grants from CD Diagnostics, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, ContraFect, TenNor Therapeutics Limited, and Shionogi.

Potential Competing Interests: Dr Patel is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST and Qvella; monies are paid to Mayo Clinic. In addition, Dr Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr Patel receives travel reimbursement from ASM and IDSA, an editor’s stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Dr Binnicker is an Advisory Board member for DiaSorin Molecular. The other authors report no competing interests.

View Abstract